Abdera Therapeutics Inc. is a precision oncology company developing next-generation targeted radiation therapies - one of the most cutting-edge and highly promising areas of drug development. The company is built on a proprietary modular technology platform optimized for the delivery of radioisotopes to selectively destroy tumor cells while sparing healthy cells. Abdera is using this platform to enable the rapid development of a broad range of safe and efficacious therapies serving cancer patients with limited treatment options. Abdera Therapeutics is growing rapidly and seeking key new team members who thrive at the cutting-edge of innovation. Come join us and be a part of the ground-breaking team set to unlock the power of targeted radiotherapy!

Ability Biologics is a leading biotherapeutic targeting company focused on developing innovative, immune-modulating biotherapeutics to address unmet medical needs in cancer and autoimmune diseases. Utilizing their proprietary Abi Leap™ discovery engine, they produce fully human, Ig G-based multispecific antibodies with exceptional selectivity and affinity. Their technology leverages artificial intelligence and a vast database of antigen-antibody interactions to create highly specific therapeutics. The company is dedicated to advancing preclinical antibody candidates and aims to conduct human proof of concept clinical trials, positioning itself as a key player in the biotherapeutics market.

Amplitude Venture Capital deploys a growth model that has successfully been used to build Canadian companies with world-class management teams and scale companies to breakout potential. Since 2012 Amplitude's founding team has raised over $700 million of equity capital in private and public markets. Amplitude, with offices in Montreal, Toronto, and Vancouver, launched its first private capital fund in November 2019, a $200-million fund that applies a proven, evidence-based approach to investing in leading Canadian precision medicine companies.

Congruence Therapeutics is a drug discovery company that leverages protein dynamics, biophysics, machine learning, and computational chemistry to create predictive models for drug design. Their innovative Revenir™ Product Engine allows for the visualization of proteins in their dynamic states, enabling the design of small molecules aimed at treating diseases caused by protein misfolding. With a focus on high unmet medical needs, Congruence is positioned to transform drug discovery and improve patient outcomes.

Deep Genomics is an AI-driven genetic medicine company that focuses on programming RNA therapies for any gene and genetic condition. Their proprietary AI platform, Big RNA, enables the discovery of novel therapeutic candidates by untangling the complexities of RNA biology. With a strong interdisciplinary team of over 100 experts, they have made significant advancements in RNA therapeutic development, including the release of the first Foundation Model for RNA Biology. The company is positioned at the forefront of drug development, leveraging AI to address complex genetic diseases and has received recognition as a leading biotechnology company.

DrugBank augments human intelligence to improve the world’s health. Our suite of products are powered by the world’s most complete and up-to-date pharmaceutical knowledge database. It includes everything there is to know about drugs and how they work in the body. We enable companies to improve healthcare delivery through precision medicine or clinical software applications, as well as uncover insights through data science in drug discovery. Our knowledge base can be integrated into software solutions to help achieve clinical intelligence. Companies can easily scale their usage through our API and launch faster with flexible data modules. By providing users with advanced insights and the right information at the right time, users are empowered to make better health decisions. Our extensive, structured datasets are used to discover novel drug candidates, identify drug repurposing opportunities, and build predictive machine learning models. Companies working with data science can find answers quickly and get drugs to market faster with our evidence-based drug information. Lastly, our publicly available resource, DrugBank Online, is free-to-use with limited datasets available for download for academic and non-commercial researchers. DrugBank has been cited in over 13,000 academic publications and is used by millions of researchers and health professionals globally.

Evommune is focused on discovering and developing novel therapies for chronic inflammatory diseases, targeting the root causes of inflammation with a robust pipeline that includes the MRGPRX2 Antagonist, IL-18 Fusion Protein, and PKCθ Inhibitor. The company aims to address the high unmet needs in underserved patient populations, leveraging extensive R&D expertise in immunology to deliver therapeutics that go beyond symptomatic relief. With a commitment to advancing clinical-stage pipelines, Evommune is positioned to make significant impacts in the treatment of chronic inflammatory diseases, which are increasingly recognized as a global health crisis.

Gandeeva Therapeutics is a precision biotechnology company leveraging artificial intelligence and cryogenic electron microscopy to develop innovative therapies targeting protein interactions. Their unique platform focuses on creating precision medicines for challenging diseases, particularly in oncology, through proximity-inducing glues and engineered antibodies. With a robust pipeline and a team of experts in structural biology and drug discovery, Gandeeva aims to transform the landscape of drug development and improve patient outcomes.

Nomic is a bioengineering company revolutionizing protein profiling with its n ELISA platform, enabling high-throughput and flexible multiplexing for comprehensive immune secretome analysis. Their innovative technology allows for the profiling of over 200 cytokines, achieving a throughput of 10,000+ samples per week, making it the fastest and most seamless protein profiling service available. Nomic's differentiation lies in its ability to provide true multiplexing without cross-reactivity issues, offering a cost-effective solution that meets the growing demand in the life sciences sector. With significant traction and partnerships, Nomic is positioned as a leader in the proteomics market, facilitating advancements in drug discovery and immunotherapy research.

Notch Therapeutics is pioneering the development of best-in-class T cell therapies through its innovative UNi-T Cell, derived from induced pluripotent stem cells (iPSCs). This off-the-shelf solution addresses significant challenges in adoptive cell therapy, providing a uniform, cost-effective, and accessible CAR-T option for a broader patient population. By eliminating the need for costly and variable patient-specific modifications, Notch aims to enhance patient experience and access to advanced cancer treatments. With a focus on scalability and commercial viability, Notch is positioned to transform the landscape of cell therapy, making it a compelling investment opportunity in the biopharmaceutical sector.

Prilenia is a clinical-stage biotech company focused on developing novel treatments for neurodegenerative and neurodevelopmental disorders. Our lead asset is Pridopidine, a first-in-class oral drug candidate with an established safety profile and potential in multiple movement disorders and neurodegenerative diseases affecting adults and children. Pridopidine is currently being evaluated for the treatment of Huntington’s disease in our global Phase 3 PROOF-HD trial, and for the treatment of ALS in the Phase 2/3 Healey Platform trial. The company is led by Dr. Michael Hayden, MD, PhD, the founder of five biotech companies and previous President of Global R&D and Chief Scientific Officer at Teva. Michael has directed the development of multiple innovative drug products, leading to 35 approvals between 2012-2018. The company is based in Naarden, the Netherlands, Herzliya, Israel, and Boston, MA in the U.S.

Repare Therapeutics is a leading clinical-stage precision oncology company focused on synthetic lethality. Utilizing their proprietary SNIPRx® platform, they systematically discover and develop targeted cancer therapies that address genomic instability, particularly in DNA damage repair. Founded in 2016 by leading academics, the company aims to be a leader in biopharmaceuticals by developing small molecule therapies based on synthetic lethality, identifying novel targets, designing selective inhibitors, and expanding treatment options for patients with high unmet medical needs.